Literature DB >> 18983947

Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1-84.

R R Recker1, S P Bare, S Y Smith, A Varela, M A Miller, S A Morris, J Fox.   

Abstract

Treatment with parathyroid hormone [PTH(1-84)] increases lumbar spine bone mineral density and decreases vertebral fractures, but its effects on bone microarchitecture are unknown. We obtained iliac crest biopsies from postmenopausal osteoporotic women given placebo (n=8) or 100 microg PTH(1-84) for 18 (n=8) or 24 (n=7) months to assess cancellous and cortical bone formation and structure. At 18 months, cancellous bone volume (BV/TV) measured by microcomputed tomography and histomorphometry was 45-48% higher in subjects treated with PTH(1-84) versus placebo, a result of higher trabecular number (Tb.N) and thickness. The higher Tb.N appeared to result from intratrabecular tunneling. Connectivity density was higher and structure model index was lower, indicating a better connected and more plate-like trabecular architecture. Cancellous bone formation rate (BFR) was 2-fold higher in PTH(1-84)-treated subjects, primarily because of greater mineralizing surface. Osteoblast and osteoid surfaces were a nonsignificant 58% and 35%, respectively, higher with PTH(1-84) treatment. Osteoclast and eroded surface were unaffected by PTH(1-84). There were no effects of PTH(1-84) treatment on cortical thickness, or endocortical or periosteal BFR, but cortical porosity tended to be higher. Although cancellous BFR was lower at 24 than at 18 months, measures of cancellous and cortical bone structure were similar at both timepoints. The bone produced by PTH(1-84) had normal lamellar structure and mineralization with no abnormal histology. In conclusion, when compared with placebo, treatment of osteoporotic women with PTH(1-84) was associated with higher BV/TV and trabecular connectivity, with a more plate-like architecture, all consistent with the lower vertebral fracture incidence.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18983947     DOI: 10.1016/j.bone.2008.09.019

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  36 in total

Review 1.  Catabolic and anabolic actions of parathyroid hormone on the skeleton.

Authors:  B C Silva; A G Costa; N E Cusano; S Kousteni; J P Bilezikian
Journal:  J Endocrinol Invest       Date:  2011-09-23       Impact factor: 4.256

2.  Parathyroid hormone therapy for hypoparathyroidism.

Authors:  Natalie E Cusano; Mishaela R Rubin; John P Bilezikian
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2014-09-10       Impact factor: 4.690

Review 3.  Skeletal changes through the lifespan--from growth to senescence.

Authors:  Joshua N Farr; Sundeep Khosla
Journal:  Nat Rev Endocrinol       Date:  2015-06-02       Impact factor: 43.330

4.  PTH(1-84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism.

Authors:  Mishaela R Rubin; David W Dempster; James Sliney; Hua Zhou; Thomas L Nickolas; Emily M Stein; Elzbieta Dworakowski; Maryann Dellabadia; Rebecca Ives; Donald J McMahon; Chiyuan Zhang; Shonni J Silverberg; Elizabeth Shane; Serge Cremers; John P Bilezikian
Journal:  J Bone Miner Res       Date:  2011-11       Impact factor: 6.741

Review 5.  The effect of antiresorptives on bone quality.

Authors:  Robert R Recker; Laura Armas
Journal:  Clin Orthop Relat Res       Date:  2011-08       Impact factor: 4.176

Review 6.  Bone quality and bone strength: benefits of the bone-forming approach.

Authors:  Giovanni Iolascon; Laura Frizzi; Gioconda Di Pietro; Annarita Capaldo; Fabrizio Luciano; Francesca Gimigliano
Journal:  Clin Cases Miner Bone Metab       Date:  2014-01

7.  Development of new criteria for cortical bone histomorphometry in femoral neck: intra- and inter-observer reproducibility.

Authors:  Xiao-Yu Tong; Markus Malo; Inari S Tamminen; Hanna Isaksson; Jukka S Jurvelin; Heikki Kröger
Journal:  J Bone Miner Metab       Date:  2014-02-26       Impact factor: 2.626

8.  The effect of PTH(1-84) or strontium ranelate on bone formation markers in postmenopausal women with primary osteoporosis: results of a randomized, open-label clinical trial.

Authors:  J M Quesada-Gómez; C Muschitz; J Gómez-Reino; H Greisen; H S Andersen; H P Dimai
Journal:  Osteoporos Int       Date:  2010-10-30       Impact factor: 4.507

9.  Osteopontin regulates anabolic effect in human menopausal osteoporosis with intermittent parathyroid hormone treatment.

Authors:  T-I Chiang; I-C Chang; H-S Lee; H Lee; C-H Huang; Y-W Cheng
Journal:  Osteoporos Int       Date:  2010-08-24       Impact factor: 4.507

10.  Mesenchymal progenitors residing close to the bone surface are functionally distinct from those in the central bone marrow.

Authors:  Valerie A Siclari; Ji Zhu; Kentaro Akiyama; Fei Liu; Xianrong Zhang; Abhishek Chandra; Hyun-Duck Nah; Songtao Shi; Ling Qin
Journal:  Bone       Date:  2012-12-27       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.